{
  "items": "24",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "How Coeptis Therapeutics Holdings Inc. (COEP) Affects Rotational Strategy Timing",
      "url": "https://news.stocktradersdaily.com/news_release/20/How_Coeptis_Therapeutics_Holdings_Inc._COEP_Affects_Rotational_Strategy_Timing_122625102401_1766805841.html",
      "time_published": "20251226T222400",
      "authors": [
        "Jeff W."
      ],
      "summary": "This article analyzes Coeptis Therapeutics Holdings Inc. (COEP) through a rotational strategy timing lens, highlighting positive near-term sentiment while noting a mid-channel oscillation pattern. It presents an exceptional risk-reward short setup and outlines institutional trading strategies based on AI models, including position trading, momentum breakout, and risk hedging with multi-timeframe signal analysis.",
      "banner_image": "https://news.stocktradersdaily.com/media/694888_COEP_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.946108"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.801609"
        }
      ],
      "overall_sentiment_score": 0.223299,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "0.965291",
          "ticker_sentiment_score": "0.211693",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is Coeptis Therapeutics Holdings Inc. Equity Warrant stock a contrarian buy - July 2025 Earnings & Fast Entry Momentum Trade Alerts",
      "url": "http://ulpravda.ru/blank/Is-Coeptis-Therapeutics-Holdings-Inc.-Equity-Warrant-stock-a-contrarian-buy",
      "time_published": "20251218T220851",
      "authors": [],
      "summary": "This article poses the question of whether Coeptis Therapeutics Holdings Inc. Equity Warrant stock is a contrarian buy. It also includes several unrelated inserts about general \"Equity Investments\" promotions, environmental conservation efforts in Hong Kong, US President Joe Biden's criticism of Congress, and a Hong Kong celebrity's personal life choices. The article does not provide any specific financial analysis or information about Coeptis Therapeutics Holdings Inc.",
      "banner_image": "https://asserts.btccryptcion.shop/asserts/english/images/watermark_20250427_5_w3.jpg",
      "source": "\u0423\u043b\u043f\u0440\u0430\u0432\u0434\u0430",
      "category_within_source": "General",
      "source_domain": "\u0423\u043b\u043f\u0440\u0430\u0432\u0434\u0430",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.912054"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.846921"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.711626"
        }
      ],
      "overall_sentiment_score": 0.116772,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.135004",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Discipline and Rules-Based Execution in COEP Response",
      "url": "https://news.stocktradersdaily.com/news_release/139/Discipline_and_Rules-Based_Execution_in_COEP_Response_121525090601_1765850761.html",
      "time_published": "20251215T210600",
      "authors": [
        "Ian Thomas Bannon"
      ],
      "summary": "This article analyzes Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details specific institutional trading strategies, including long, breakout, and short positions, based on AI-generated signals and multi-timeframe analysis. The report also outlines support and resistance levels across different time horizons for COEP.",
      "banner_image": "https://news.stocktradersdaily.com/media/686929_COEP_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.940522"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.714372"
        }
      ],
      "overall_sentiment_score": -0.236987,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.219354",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Significant Increase in Short Interest",
      "url": "https://www.marketbeat.com/instant-alerts/coeptis-therapeutics-holdings-inc-nasdaqcoep-sees-significant-increase-in-short-interest-2025-10-21/",
      "time_published": "20251021T000000",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) experienced a 76.5% increase in short interest in September, totaling 72,700 shares shorted. The company's stock traded down to $14.99 and has a market capitalization of $72.25 million. Analysts, including Weiss Ratings, collectively have a \"Sell\" rating on the stock due to its financial performance and recent stock decline.",
      "banner_image": null,
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.921660"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.845735"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.834393"
        }
      ],
      "overall_sentiment_score": -0.615522,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.634344",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "$44.39B Cell Therapy Market by 2034: Coeptis Pioneers Hybrid Revenue Model While Advancing Cancer Research",
      "url": "https://www.stocktitan.net/news/COEP/vanderbilt-report-coeptis-shows-how-biotech-can-fund-itself-while-x3g1iv1cg090.html",
      "time_published": "20250923T035155",
      "authors": [],
      "summary": "Coeptis Therapeutics (NASDAQ: COEP) is pioneering a dual-track business model, combining revenue generation with biotech innovation, as evidenced by its Q2 2025 revenue of $200,681 and advancement of the GEAR Cell Therapy Platform. The company's cash position significantly improved, and it secured exclusive worldwide rights to the GEAR Cell Therapy Platform from Karolinska Institutet. This strategy positions Coeptis in the rapidly growing NK cell therapy market, projected to reach $44.39 billion by 2034, by reducing reliance on dilutive funding while pursuing therapeutic breakthroughs.",
      "banner_image": "https://ml.globenewswire.com/media/ZTVmZGY4MDUtYjMwMS00MTljLTk0N2YtNmE3N2ZiOTgxYzA0LTUwMDE1MjIxNS0yMDI1LTA5LTIzLWVu/tiny/Vanderbilt-Report-and-Coeptis-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.919871"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.816341"
        },
        {
          "topic": "finance",
          "relevance_score": "0.715378"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.608873"
        }
      ],
      "overall_sentiment_score": 0.312388,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "0.950714",
          "ticker_sentiment_score": "0.343982",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "COEPW SEC Filings - Coeptis Therapeutics Holdings Inc 10-K, 10-Q, 8-K Forms",
      "url": "https://www.stocktitan.net/sec-filings/COEPW/",
      "time_published": "20250912T010956",
      "authors": [
        "NULL"
      ],
      "summary": "This article provides access to SEC filings for Coeptis Therapeutics Holdings Inc. (COEPW), including 10-K, 10-Q, and 8-K forms, enhanced with AI-generated summaries and impact analyses from Rhea-AI. It highlights a specific proxy filing from September 12, 2025, detailing a proposed transaction to merge Z Squared into Coeptis, involving a spin-out of biopharmaceutical operations, and other corporate actions. The filing also discloses financial details, including a $5 million termination fee and the contribution of 9,000 cryptocurrency mining machines.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.703847"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.649964"
        },
        {
          "topic": "blockchain",
          "relevance_score": "0.619977"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.834606"
        }
      ],
      "overall_sentiment_score": 0.008008,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "0.315614",
          "ticker_sentiment_score": "0.008081",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Holdings, Inc. Announces Extinguishment of Convertible Note, Strengthening Capital Structure",
      "url": "https://www.nasdaq.com/articles/coeptis-therapeutics-holdings-inc-announces-extinguishment-convertible-note-strengthening",
      "time_published": "20250722T085100",
      "authors": [
        "None for Quiver Quantitative"
      ],
      "summary": "Coeptis Therapeutics Holdings, Inc. announced the extinguishment of its convertible note with YA II PN, Ltd, clearing its outstanding debt obligations and strengthening its capital structure. This move positions the biopharmaceutical and technology company to pursue long-term goals, including potential strategic expansion into the cryptocurrency space. CEO David Mehalick highlighted that a streamlined capital structure enhances the company's ability to navigate future endeavors.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.936528"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.828349"
        },
        {
          "topic": "technology",
          "relevance_score": "0.738724"
        },
        {
          "topic": "blockchain",
          "relevance_score": "0.602915"
        }
      ],
      "overall_sentiment_score": 0.291093,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.292347",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared",
      "url": "https://www.globenewswire.com/news-release/2025/06/26/3105855/0/en/Coeptis-COEP-Announces-Filing-of-Registration-Statement-on-Form-S-4-with-SEC-in-Connection-with-Proposed-Transaction-with-Z-Squared.html",
      "time_published": "20250626T083400",
      "authors": [],
      "summary": "Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has announced the filing of a Form S-4 registration statement with the SEC regarding its proposed merger with Z Squared Inc. This filing includes a preliminary proxy statement/prospectus. The merger aims to combine Coeptis' biopharmaceutical and technology ventures with Z Squared's digital asset compute mining operations.",
      "banner_image": "https://ml.globenewswire.com/media/NjgzMTBkOGEtYjZmMC00YjQ3LWIxNzYtMTM2ODgwY2QwMmUzLTEyMTc4OTEtMjAyNS0wNi0yNi1lbg==/tiny/Coeptis-Therapeutics.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.807057"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.746058"
        },
        {
          "topic": "technology",
          "relevance_score": "0.601343"
        }
      ],
      "overall_sentiment_score": 0.032788,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "0.322214",
          "ticker_sentiment_score": "0.008251",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Files Form S-4 Registration Statement for Proposed Merger with Z Squared Inc.",
      "url": "https://www.nasdaq.com/articles/coeptis-therapeutics-files-form-s-4-registration-statement-proposed-merger-z-squared-inc",
      "time_published": "20250626T010956",
      "authors": [
        "None"
      ],
      "summary": "Coeptis Therapeutics Holdings, Inc. has filed a Form S-4 registration statement with the SEC in connection with its proposed merger with Z Squared Inc. This filing includes a preliminary proxy statement/prospectus. Coeptis, a biopharmaceutical company, is also expanding its operations with a new Technology Division, while Z Squared focuses on digital asset compute mining for Dogecoin.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.940142"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.743759"
        },
        {
          "topic": "blockchain",
          "relevance_score": "0.619724"
        },
        {
          "topic": "technology",
          "relevance_score": "0.638435"
        }
      ],
      "overall_sentiment_score": -0.091639,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.059095",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Coepis Therapeutics Holdings, Inc. Enters Definitive Merger Agreement with Z Squared Inc. to Pursue Dogecoin Mining Venture",
      "url": "https://www.quiverquant.com/news/Coeptis+Therapeutics+Holdings%2C+Inc.+Enters+Definitive+Merger+Agreement+with+Z+Squared+Inc.+to+Pursue+Dogecoin+Mining+Venture",
      "time_published": "20250425T124000",
      "authors": [],
      "summary": "Coeptis Therapeutics has announced a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. The merger will make Z Squared a wholly-owned subsidiary of Coeptis, with Z Squared shareholders receiving equity in Coeptis in exchange for 9,000 Dogecoin mining machines. Following the merger, Coeptis plans to spin out its biopharmaceutical operations to operate separately, and the combined company will rebrand as Z Squared, Inc., focusing on Dogecoin mining.",
      "banner_image": null,
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.931434"
        },
        {
          "topic": "blockchain",
          "relevance_score": "0.823759"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.734777"
        },
        {
          "topic": "finance",
          "relevance_score": "0.647586"
        }
      ],
      "overall_sentiment_score": -0.206914,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.213898",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Massive Crypto Pivot: Biotech Firm Acquires 9,000 Dogecoin Miners in Industry-Shaking Merger",
      "url": "https://www.stocktitan.net/news/COEP/coeptis-therapeutics-inc-and-z-squared-inc-announce-merger-t1vhm1q5opku.html",
      "time_published": "20250425T083300",
      "authors": [],
      "summary": "Coeptis Therapeutics has announced a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. This merger will transform Coeptis into the largest publicly-traded, Dogecoin-focused mining company globally, involving Coeptis spinning out its biopharmaceutical operations and rebranding as Z Squared, Inc. The combined entity will focus on mining Dogecoin and other digital assets, with the transaction expected to close in Q3 2025.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.926853"
        },
        {
          "topic": "blockchain",
          "relevance_score": "0.909326"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.716351"
        }
      ],
      "overall_sentiment_score": 0.171356,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.205438",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.563840",
          "ticker_sentiment_score": "0.100158",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics and Z Squared to Merge",
      "url": "https://www.citybiz.co/article/686811/coeptis-therapeutics-and-z-squared-to-merge/",
      "time_published": "20250425T000000",
      "authors": [],
      "summary": "Coeptis Therapeutics Holdings, Inc. and Z Squared Inc. have entered into a definitive merger agreement. Under the terms, Z Squared will become a wholly-owned subsidiary of Coeptis, with Z Squared shareholders receiving equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines. Coeptis plans to spin out its biopharmaceutical operations while retaining its technology operations, and the combined company will primarily focus on Dogecoin mining under the new name Z Squared, Inc.",
      "banner_image": null,
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "blockchain",
          "relevance_score": "0.903902"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.707700"
        },
        {
          "topic": "finance",
          "relevance_score": "0.640637"
        },
        {
          "topic": "technology",
          "relevance_score": "0.615406"
        }
      ],
      "overall_sentiment_score": 0.425765,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.449974",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Holdings Inc. (COEP) reports earnings",
      "url": "https://qz.com/coeptis-therapeutics-holdings-inc-coep-reports-earni-1851773004",
      "time_published": "20250328T000000",
      "authors": [
        "Quartz Intelligence Newsroom"
      ],
      "summary": "Coeptis Therapeutics Holdings Inc. (COEP) reported a reduced net loss of $10,877,412 for the fiscal year ended December 31, 2024, down from $21,266,537 in the prior year, primarily due to decreased research and development expenses. The company reported no revenue, raised $6.5 million through a preferred stock offering, and continues to develop its product pipeline while planning to raise additional capital to support operations due to its going concern qualification.",
      "banner_image": null,
      "source": "qz.com",
      "category_within_source": "General",
      "source_domain": "qz.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.914984"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.837163"
        },
        {
          "topic": "finance",
          "relevance_score": "0.616401"
        }
      ],
      "overall_sentiment_score": 0.276784,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.282893",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR\u2122 Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline",
      "url": "https://www.globenewswire.com/news-release/2025/03/11/3040592/0/en/Coeptis-Therapeutics-Secures-Worldwide-Development-and-Commercialization-Rights-to-Next-Generation-GEAR-Cell-Therapy-Platform-Strengthening-its-High-Impact-Precision-Immuno-Oncolog.html",
      "time_published": "20250311T083400",
      "authors": [],
      "summary": "Coeptis Therapeutics has secured exclusive worldwide development and commercialization rights to the GEAR\u2122 Cell Therapy Platform, a first-in-class approach to modifying cancer-targeting immune cells. As part of this agreement, Coeptis formed a new majority-owned subsidiary, GEAR Therapeutics, Inc., to advance GEAR-based cell therapy, specifically GEAR-modified natural killer cells (GEAR-NK), into human proof-of-concept studies for a broad range of cancers. This expanded ownership aims to optimize existing antibody-based cancer therapies and provide a beneficial, cost-effective therapeutic option for patients.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934596"
        },
        {
          "topic": "finance",
          "relevance_score": "0.749267"
        }
      ],
      "overall_sentiment_score": 0.498339,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.463357",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coemptis Therapeutics Holdings, Inc. (COEP) Raises $10M to Advance AI-Driven Cell Therapy Innovations",
      "url": "https://finance.yahoo.com/news/coeptis-therapeutics-holdings-inc-coep-073550774.html",
      "time_published": "20250208T073550",
      "authors": [
        "Affan Mir"
      ],
      "summary": "Coeptis Therapeutics Holdings, Inc. (COEP) has successfully raised an additional $5.7 million in its Series A Preferred Offering, bringing the total to $10 million. This funding, led by CJC Investment Trust, will bolster the company's financial standing and support the integration of AI and automation to enhance research and operational efficiency in developing cell therapies for various diseases. The article also discusses broader AI investment trends and their impact on tech stocks and regulatory environments.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "technology",
          "relevance_score": "0.823134"
        },
        {
          "topic": "finance",
          "relevance_score": "0.717282"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.901275"
        }
      ],
      "overall_sentiment_score": 0.441238,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.448558",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation",
      "url": "https://www.prnewswire.com/news-releases/coeptis-therapeutics-holdings-becomes-coeptis-embracing-a-future-of-technology-and-innovation-302364358.html",
      "time_published": "20250130T082700",
      "authors": [],
      "summary": "Coeptis Therapeutics Holdings has rebranded to COEPTIS, signaling a strategic shift beyond biopharmaceuticals into technology-driven sectors with a new Technology Division. This move includes the acquisition of the NexGenAI Affiliates Network platform, an AI-powered marketing solution, to enhance operational capabilities and maximize shareholder value. The company aims to become a self-sustaining entity by leveraging cutting-edge technologies and expanding into revenue-generating business units.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944856"
        },
        {
          "topic": "technology",
          "relevance_score": "0.815431"
        },
        {
          "topic": "finance",
          "relevance_score": "0.602838"
        }
      ],
      "overall_sentiment_score": 0.520571,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.512521",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Thx to Pursue Phase 2 Trial with Cord-Blood Derived NK Cells",
      "url": "https://bioinformant.com/coeptis-therapeutics-allogeneic-nk-cell-therapy/",
      "time_published": "20240313T000000",
      "authors": [
        "Cade Hildreth"
      ],
      "summary": "Coeptis Therapeutics announced plans to advance DVX201, its allogeneic cord-blood derived NK cell therapy, into a Phase 2 clinical program for severe respiratory viral infections like influenza, COVID-19, and RSV. The therapy aims to bolster patients' immune systems, with favorable Phase 1 results showing DVX201 to be well-tolerated with no dose-limiting toxicities. This novel approach seeks to address the \"tripledemic\" and support the strained healthcare system by providing a potential treatment for hospitalized high-risk patients.",
      "banner_image": null,
      "source": "BioInformant",
      "category_within_source": "General",
      "source_domain": "BioInformant",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.523776,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.547357",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (2024-02-26)",
      "url": "https://seekingalpha.com/pr/19633921-coeptis-therapeutics-adds-autoimmune-indications-to-exclusive-license-agreement-with",
      "time_published": "20240226T090000",
      "authors": [],
      "summary": "Coeptis Therapeutics has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for its SNAP-CAR T and SNAP-CAR NK technology platforms. This expansion aims to target the multibillion-dollar autoimmune disease market, leveraging research that suggests CAR T cells effective in B cell malignancies can also target autoreactive B cells causing autoimmune diseases. The company believes its SNAP-CAR technologies have the potential to revolutionize autoimmune disease treatment by targeting multiple antigens.",
      "banner_image": null,
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.920011"
        }
      ],
      "overall_sentiment_score": 0.480405,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.471343",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Could Revolutionize The Treatment of Cancer",
      "url": "https://smallcapexclusive.com/coeptis-therapeutics-could-revolutionize-the-treatment-of-cancer/",
      "time_published": "20231231T235959",
      "authors": [],
      "summary": "Coeptis Therapeutics (NASDAQ: COEP) is presented as a biopharmaceutical company with innovative treatments for cancer, particularly in cell therapy. The article highlights a price target of over $6 by Jones Trading, suggesting significant upside potential from current levels. Key catalysts include a bullish stock chart, proprietary drug delivery systems (CDS), and revolutionary product candidates like CTX-4430 and several CAR-T and NK cell therapies aiming to disrupt cancer treatment paradigms.",
      "banner_image": null,
      "source": "Small Cap Exclusive",
      "category_within_source": "General",
      "source_domain": "Small Cap Exclusive",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.907096"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.723345"
        }
      ],
      "overall_sentiment_score": 0.493394,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.458485",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis CEO Dave Mehalick on NASDAQ listing and entering the Cancer Treatment Race",
      "url": "https://investornews.com/biotech-medtech/coeptis-ceo-dave-mehalick-on-nasdaq-listing-and-entering-the-cancer-treatment-race/",
      "time_published": "20231228T000000",
      "authors": [],
      "summary": "Dave Mehalick, CEO of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), discusses the company's progress in cancer therapy since its NASDAQ listing a year ago. Coeptis boasts three innovative cell therapy platforms acquired from top institutions, aiming to universalize and make cancer treatment more accessible. Mehalick highlights the company's strong capital structure, globally recognized scientists, and promising technologies currently undergoing positive studies.",
      "banner_image": null,
      "source": "InvestorNews",
      "category_within_source": "General",
      "source_domain": "InvestorNews",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.835624"
        },
        {
          "topic": "finance",
          "relevance_score": "0.641674"
        }
      ],
      "overall_sentiment_score": 0.49992,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.461624",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis appoints Colleen Delaney as chief scientific and medical officer",
      "url": "https://www.bizjournals.com/bizwomen/news/latest-news/2023/09/coeptis-appoints-chief-scientific-medical-officer.html",
      "time_published": "20230905T000000",
      "authors": [
        "Nate Doughty"
      ],
      "summary": "Coeptis Therapeutics has appointed Colleen Delaney as its chief scientific and medical officer. Delaney brings over two decades of experience as an oncologist and stem cell transplant physician-scientist, having also served on several federal advisory committees focused on cell and gene therapy. Her extensive background includes leadership roles at various nonprofit associations.",
      "banner_image": null,
      "source": "The Business Journals",
      "category_within_source": "General",
      "source_domain": "The Business Journals",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.945918"
        }
      ],
      "overall_sentiment_score": 0.317101,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.316186",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer",
      "url": "https://www.prnewswire.com/news-releases/coeptis-therapeutics-appoints-colleen-delaney-md-as-chief-scientific-and-medical-officer-301914013.html",
      "time_published": "20230830T130000",
      "authors": [],
      "summary": "Coeptis Therapeutics appointed Colleen Delaney, MD, as Chief Scientific and Medical Officer following an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform. Dr. Delaney brings over two decades of experience in oncology and stem cell transplant, with expertise in cell therapy product development and clinical trial design. Her appointment is expected to significantly contribute to Coeptis's goal of developing impactful off-the-shelf cellular immunotherapies for cancer and infectious diseases.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929079"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.844176"
        }
      ],
      "overall_sentiment_score": 0.43864,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.436490",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics",
      "url": "https://www.prnewswire.com/news-releases/coeptis-therapeutics-completes-exclusive-license-for-allogeneic-immuno-oncology-platform-and-clinical-stage-assets-from-deverra-therapeutics-301903022.html",
      "time_published": "20230817T073000",
      "authors": [],
      "summary": "Coeptis Therapeutics has completed an exclusive license agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical-stage assets. This transaction bolsters Coeptis' pipeline with two Phase 1 clinical stage assets utilizing NK cell therapies and preclinical programs for various cancers, making Coeptis a clinical-stage company. The deal involved Coeptis paying Deverra $570,000 in cash and issuing 4,000,000 shares of its common stock.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938771"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.828664"
        },
        {
          "topic": "finance",
          "relevance_score": "0.636346"
        }
      ],
      "overall_sentiment_score": 0.468621,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.451977",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.",
      "url": "https://www.prnewswire.com/news-releases/coeptis-therapeutics-inc-announces-closing-of-business-combination-with-bull-horn-holdings-corp-301662851.html",
      "time_published": "20221031T070000",
      "authors": [],
      "summary": "Coeptis Therapeutics, a biopharmaceutical company, announced the completion of its business combination with Bull Horn Holdings Corp. The combined entity, now named Coeptis Therapeutics Holdings, Inc., will begin trading on the Nasdaq Global Market under the ticker symbol \"COEP\" and will focus on developing innovative cell therapy platforms for cancer. David Mehalick will lead the new company as CEO and Chairman, emphasizing the uplift to Nasdaq to enhance visibility and liquidity.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.912947"
        }
      ],
      "overall_sentiment_score": 0.476527,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COEP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.479777",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}